

Current Disease Modifying Therapies for Active SPMS

- All DMTs approved for RRMS are also approved for **active** SPMS¹
- No FDA-approved DMTs for **nonactive** SPMS¹
- Of current agents for **active** SPMS, only the S1P receptor modulator **siponimod** delayed progression in clinical trials enrolling only patients with progressive MS²

Approved for treatment of RRMS and active SPMS^{1,3,4}

Modulation of immune cell pathways and function

Glatiramer acetate

Interferon beta (1a and 1b)

Fumarates (dimethyl, diroximel, and monomethyl)

Reduced cell proliferation

Teriflunomide

(Mitoxantrone*)

Altered immune cell trafficking

Natalizumab (anti-integrin)

S1P receptor modulators

Fingolimod, ozanimod, ponesimod, siponimod

Targeted cell lysis/depletion

Alemtuzumab (anti-CD52)

Oral cladribine

Ocrelizumab, ofatumumab, ublituximab (anti-CD20)

*Mitoxantrone is mentioned in parentheses for thoroughness. It is rarely used in North America due to safety concerns.


DMT, disease-modifying therapy; RRMS, relapsing-remitting multiple sclerosis; S1P, sphingosine 1-phosphate; SPMS, secondary progressive multiple sclerosis.

1. Amezcua L. *Continuum (Minneap Minn)*. 2022;28:1083-1103; 2. Yong HYF et al. *Nat Rev Neurol*. 2022;18:40-55; 3. Fischer S et al. *Cells*. 2021;10:3177;

4. Briumvi (ublituximab xiiy) prescribing information. TG Therapeutics, Inc: Morrisville, NC. 2022.

Current Disease Modifying Therapies for PPMS

- The anti-CD20 antibody **ocrelizumab** is the only DMT FDA-approved for treatment of PPMS¹
- Ocrelizumab is also approved for the treatment of RRMS and active SPMS²



DMT, disease-modifying therapy; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; secondary progressive multiple sclerosis.

1. Amezcua L. *Continuum (Minneap Minn)*. 2022;28:1083-1103; 2. Ocrevus® (ocrelizumab). Prescribing information. Genentech, Inc; March 2023.

Illustration adapted from Stathopoulos P et al. *Neurotherapeutics*. 2022;19:691-710. Copyright© 2022 by the authors ([CC BY 4.0](#)).